Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
Date:9/22/2010

R 20 response criteria is defined as greater than or equal to 20% improvement from baseline in both tender and swollen joints, and greater than or equal to 20% improvement in three of five measures: pain, acute phase reactant, physical function, patient and physician global assessment. ACR 50 and ACR 70 assess greater than or equal to 50% improvement and greater than or equal to 70% improvement in those areas respectively. ** DAS 28 is a measure of the activity of Rheumatoid Arthritis assessing 28 joint counts in the body

About Fostamatinib

Fostamatinib (previously referred to as R788), is the first oral syk inhibitor in development as a novel therapeutic approach for RA. It is thought to reversibly block signalling in multiple cell types involved in inflammation and tissue degradation in RA.

In February 2010, AstraZeneca and Rigel Pharmaceuticals announced a worldwide license agreement whereby AstraZeneca will develop and commercialise fostamatinib.

About RA

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, which causes damage to the joints and other organs, affecting approximately 1 in 100 people. It is a major cause of disability and is also associated with reduced life expectancy, especially if not adequately treated.

About the TASKi2 Study Design

TASKi2 was a 6 month, multi-center, randomized, double-blind, placebo controlled, parallel dose clinical trial involving 457 RA patients in the U.S., Latin America and Europe who had active RA despite treatment with MTX alone. Approximately 1/3 of the patients (n=152) studied received 100mg of fostamatinib orally bid. Another third received 150mg of the study drug qd and the final third were given placebo to be taken orally bid or qd (total placebo n=153). Throughout the study all patients continued to receive their stable dose of MTX.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business wit
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Corporation (NASDAQ: NEOG ) announced today that it has ... food testing laboratory based in southwest India ... base for the company,s new operations in India ... was incorporated in 1990, and its business has grown to ... testing for major hotels and restaurants in its home region, ...
(Date:6/1/2015)... - Resverlogix Corp. (TSX: RVX) (the "Company") today announced ... ERA-EDTA Congress in London, England ... Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with ... a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension at ...
(Date:6/1/2015)...  Berg, a biopharmaceutical company committed to uncovering health ... from its trials using its cancer drug BPM 31510 ... triple negative breast cancer, at the 51 st ... (ASCO), May 29 – June 2 in ... one of the first cancer drugs guided in development ...
(Date:6/1/2015)... 2015 Shire plc (LSE: SHP, ... participating in the Jefferies 2015 Global Healthcare Conference in ... June 2, 2015. Jeff Poulton , Chief Financial ... at 10:00 a.m. ET (3:00 p.m. BST). ... Presentations and Webcasts section of Shire,s Investor website at ...
Breaking Biology Technology:Neogen acquires India food safety company 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
... 15, 2011 diaDexus, Inc. (OTC Bulletin Board: ... commercialization of patent-protected in vitro diagnostic products addressing ... the second quarter of 2011. Total revenues for ... 45% growth over total revenues of $2.6 million for the ...
... 3-V Biosciences, Inc. announced today the appointment of ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "We are ... of the 3-V senior management team," said Merdad V. ... experience in drug discovery and development, as well as ...
... CA (July 1, 2011) After Fukushima, it is now ... - from cradle to grave. If nuclear waste management is ... countries will reject nuclear power as an energy choice, according ... the Atomic Scientists , published by SAGE. According to ...
Cached Biology Technology:diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 2diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 3diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 4diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter 53-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer 2Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/25/2015)... , May 25, 2015  Australia,s market for wearable ... although 2014 saw the advent of several trials and ... April 2015 is expected to ignite interest in wearables ... Australia . This in turn will ... and drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... Providing food security, one of the greatest challenges ... the developing world, where crop destruction by drought, disease ... risk of hunger. Scientists at the University of ... on cowpea, a protein-rich legume crop of immense importance ...
... NJ Uncover the neural communication links involved in ... it may become possible to reverse the breakdown of ... multiple sclerosis, spinal cord injuries, diabetes and cancers of ... the New Jersey Commission on Spinal Cord Injury and ...
... 14 satellites currently in orbit and the National Aeronautics ... been able to observe the Earths environment to help ... The use of remote sensing technology aids specialists ... common and deadly infectious diseases today such as Ebola, ...
Cached Biology News:UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 2UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 3UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 4Rutgers scientist's research reveals critical knowledge about the nervous system 2NASA technology helps predict and prevent future pandemic outbreaks 2
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Bovine Calf Serum...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
...
Biology Products: